Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response

• Yudistiro Ryan

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine Department of Nuclear Medicine, MRCCC Siloam Hospital, School of Medicine of Universitas Pelita Harapan

• Heryanto Yusri Dwi

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Kodaira Sayaka

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Higuchi Tetsuya

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Arisaka Yukiko

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Tokue Azusa

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Taketomi-Takahashi Ayako

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

• Tsukamoto Norifumi

  Oncology Center, Gunma University Hospital

• Yokohama Akihiko

  Blood Transfusion Services, Gunma University Hospital

• Handa Hiroshi

  Department of Hematology, Gunma University Hospital

• Koiso Hiromi

  Infection Control and Prevention Center, Gunma University Hospital

• Ishizaki Takuma

  Department of Hematology, Gunma University Hospital

• Tsushima Yoshito

  Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

書誌事項

タイトル別名

• Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of ⁹⁰Y-Ibritumomab Tiuxetan Response

抄録

Background and Aims: Radioimmunotherapy (RIT) appears as one of the most effective treatment options for patients with relapsed or resistant non-Hodgkin's lymphoma (NHL). Our aim was to evaluate the role of pre-RIT ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) as an early predictor of ⁹⁰Y-Ibritumomab tiuxetan treatment response. Methods: We included consecutive 20 patients with relapsed NHL (10 males; mean age, 58.5±8.9 years old) who were treated with ⁹⁰Y-Ibritumomab tiuxetan. FDG-PET/CT was performed before and after treatment. Semiquantitative parameters of all measurable FDG-avid lesions were measured and averaged. A measurable FDG-avid lesion was defined as a lesion that showed FDG uptake higher than liver with a diameter more than 1cm. Treatment response was determined by visual assessment based on a five-point score criteria from FDG-PET/CT after treatment. Results: Fourteen patients (70%) were classified as responders and the other six patients (30%) as non-responders. All semiquantitative parameters except for MTV demonstrated significantly lower values in the responders compared with the non-responders (p<0.05). Conclusions: Semiquantitative evaluation by SUVmax, SUVpeak, and TLG before treatment were useful as early predictors of ⁹⁰Y-Ibritumomab tiuxetan treatment response.

収録刊行物

• 北関東医学

  北関東医学 68 (3), 151-156, 2018-08-01

  北関東医学会

キーワード

• non-Hodgkin lymphoma
• radioimmunotherapy
• ⁹⁰Y-Ibritumomab tiuxetan
• FDG-PET/CT
• response predictor

詳細情報

• CRID: 1390001288074372224
• NII論文ID: 130007496078
• NII書誌ID: AN10585677
• DOI: 10.2974/kmj.68.151
• ISSN: 18811191
• ISSN: 13432826
• HANDLE: 10087/12770
• NDL書誌ID: 029218113
• Web Site: https://gunma-u.repo.nii.ac.jp/records/9122
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I029218113
• Web Site: https://www.jstage.jst.go.jp/article/kmj/68/3/68_151/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2019301958
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • IRDB
  • NDL
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可